PAVmed (PAVM) Competitors

PAVmed has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, TELA Bio has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

In the previous week, TELA Bio had 2 more articles in the media than PAVmed. MarketBeat recorded 5 mentions for TELA Bio and 3 mentions for PAVmed. TELA Bio's average media sentiment score of 0.64 beat PAVmed's score of 0.00 indicating that TELA Bio is being referred to more favorably in the news media.

19.9% of PAVmed shares are held by institutional investors. Comparatively, 94.3% of TELA Bio shares are held by institutional investors. 5.8% of PAVmed shares are held by insiders. Comparatively, 4.7% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PAVmed currently has a consensus price target of $65.00, suggesting a potential upside of 734.62%. TELA Bio has a consensus price target of $2.20, suggesting a potential upside of 90.48%. Given PAVmed's higher possible upside, equities analysts clearly believe PAVmed is more favorable than TELA Bio.

PAVmed has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

PAVmed has a net margin of 564.79% compared to TELA Bio's net margin of -48.37%. PAVmed's return on equity of -242.99% beat TELA Bio's return on equity.

PAVmed has a net margin of 564.79% compared to Predictive Oncology's net margin of -185,476.72%. Predictive Oncology's return on equity of 0.00% beat PAVmed's return on equity.

PAVmed has higher earnings, but lower revenue than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

PAVmed has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 3.45, indicating that its stock price is 245% more volatile than the S&P 500.

PAVmed currently has a consensus price target of $65.00, indicating a potential upside of 734.62%. Given PAVmed's stronger consensus rating and higher possible upside, research analysts plainly believe PAVmed is more favorable than Predictive Oncology.

In the previous week, PAVmed and PAVmed both had 3 articles in the media. Predictive Oncology's average media sentiment score of 0.13 beat PAVmed's score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the news media.

19.9% of PAVmed shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 5.8% of PAVmed shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PAVmed has a consensus price target of $65.00, suggesting a potential upside of 734.62%. Given PAVmed's stronger consensus rating and higher probable upside, analysts clearly believe PAVmed is more favorable than Precision Optics.

Precision Optics has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

PAVmed has a net margin of 564.79% compared to Precision Optics' net margin of -28.33%. Precision Optics' return on equity of -60.56% beat PAVmed's return on equity.

PAVmed has lower revenue, but higher earnings than Precision Optics. Precision Optics is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

13.7% of Precision Optics shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 14.4% of Precision Optics shares are held by company insiders. Comparatively, 5.8% of PAVmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, PAVmed had 2 more articles in the media than Precision Optics. MarketBeat recorded 3 mentions for PAVmed and 1 mentions for Precision Optics. Precision Optics' average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score.

PAVmed has a net margin of 564.79% compared to PetVivo's net margin of -902.82%. PAVmed's return on equity of -242.99% beat PetVivo's return on equity.

PetVivo has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 10.8% of PetVivo shares are owned by company insiders. Comparatively, 5.8% of PAVmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, PAVmed had 1 more articles in the media than PetVivo. MarketBeat recorded 3 mentions for PAVmed and 2 mentions for PetVivo. PetVivo's average media sentiment score of 0.00 equaled PAVmed'saverage media sentiment score.

PAVmed has lower revenue, but higher earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

PAVmed has a consensus price target of $65.00, indicating a potential upside of 734.62%. Given PAVmed's stronger consensus rating and higher probable upside, analysts clearly believe PAVmed is more favorable than PetVivo.